Q-omics provides the consensus-scored DCTD profile across patient tissues and cancer cell-line models. DCTD expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, DCTD is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, DCTD RNA expression shows 19,766 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, COAD, and ACC as cancer lineages where DCTD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCTD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCTD survival associations across molecular data types. DCTD RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCTD RNA expression–survival associations across cancer types. High DCTD expression shows unfavorable associations in LGG, ACC, CESC, LUAD, UVM and PAAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for DCTD RNA expression.
This table summarizes DCTD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DCTD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCTD shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, CHOL, LUAD and STAD. The COAD box plot shows higher DCTD RNA expression in tumor versus normal tissue (log2 FC = +1.133, t-test p < 0.001).
This table shows molecular features associated with DCTD in patient tissues and cancer cell lines. In patient samples, DCTD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DCTD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
